Mohammad Hossein Yazdi1, Mehdi Mahdavi2,3, Elnaz Faghfuri1, Mohammad Ali Faramarzi1, Zargham Sepehrizadeh1, Zuhair Mohammad Hassan4, Mehdi Gholami1, Ahmad Reza Shahverdi1. 1. Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, Iran. 2. Department of Immunology, Pasteur Institute of Iran, Tehran, Iran. 3. Recombinant Vaccine Research Center, Tehran University of Medical Sciences, Tehran, Iran. 4. Department of Immunology, Faculty of Medical Sciences, Tarbiat Modaress University, Tehran, Iran.
Abstract
BACKGROUND: Tumor associated antigens can be viably used to enhance host immune response. OBJECTIVES: The immunomodulatory effect of biogenic selenium nanoparticles (SeNPs) was compared between treated and untreated mice with crude antigens of 4T1 cells. MATERIALS AND METHODS: Female inbred BALB/c mice (60) were injected by cancinogenic 4T1 cells causing breast cancer. After 10 days, all tumor bearing mice were divided into 4 groups. Group 1 was daily provided oral PBS and injected by the same buffer after tumor induction and was considered as control. Group 2 received only 100 μg/day SeNPs as an oral supplement for 30 days. Group 3 was only injected with 4T1 cells crude antigens with nil supplementation of SeNPs. Group 4 animals were supplemented 100 μg/day SeNPs for 30 days and simultaneously injected with crude antigens of 4T1 cells. All antigens or PBS injections were introduced at 7, 14 and 28 days following tumor induction. Oral PBS and SeNPs supplementation initiated from the first day of tumor induction and continued up to 30 days. During tumor growth, animal weights and survival rates were monitored and at the end of the study the concentrations of different cytokines and DTH responses were measured. RESULTS: Data clearly showed that the levels of cellular immunomodulatory components (granzyme B, IL-12, IFN-γ, and IL-2) significantly increased (P < 0.05) in mice treated with both SeNPs and crude antigens of 4T1 cells in comparison to the other groups. In contrast, the levels of TGF-β in these mice decreased. CONCLUSIONS: Although SeNPs showed a noticeable boosting effect for the immune response in mice bearing tumor exposed to crude antigens of 4T1 cells, further complementary studies seem to be inevitable.
BACKGROUND:Tumor associated antigens can be viably used to enhance host immune response. OBJECTIVES: The immunomodulatory effect of biogenic selenium nanoparticles (SeNPs) was compared between treated and untreated mice with crude antigens of 4T1 cells. MATERIALS AND METHODS: Female inbred BALB/c mice (60) were injected by cancinogenic 4T1 cells causing breast cancer. After 10 days, all tumor bearing mice were divided into 4 groups. Group 1 was daily provided oral PBS and injected by the same buffer after tumor induction and was considered as control. Group 2 received only 100 μg/day SeNPs as an oral supplement for 30 days. Group 3 was only injected with 4T1 cells crude antigens with nil supplementation of SeNPs. Group 4 animals were supplemented 100 μg/day SeNPs for 30 days and simultaneously injected with crude antigens of 4T1 cells. All antigens or PBS injections were introduced at 7, 14 and 28 days following tumor induction. Oral PBS and SeNPs supplementation initiated from the first day of tumor induction and continued up to 30 days. During tumor growth, animal weights and survival rates were monitored and at the end of the study the concentrations of different cytokines and DTH responses were measured. RESULTS: Data clearly showed that the levels of cellular immunomodulatory components (granzyme B, IL-12, IFN-γ, and IL-2) significantly increased (P < 0.05) in mice treated with both SeNPs and crude antigens of 4T1 cells in comparison to the other groups. In contrast, the levels of TGF-β in these mice decreased. CONCLUSIONS: Although SeNPs showed a noticeable boosting effect for the immune response in mice bearing tumor exposed to crude antigens of 4T1 cells, further complementary studies seem to be inevitable.
Entities:
Keywords:
Breast cancer; Immune response; Immunomodulation; SeNPs; Th1 response
Authors: Mohammad Hossein Yazdi; Mohammad Mehdi Soltan Dallal; Zuhair Mohammad Hassan; Marzieh Holakuyee; Solmaz Agha Amiri; Mohsen Abolhassani; Mehdi Mahdavi Journal: Br J Nutr Date: 2010-03-02 Impact factor: 3.718
Authors: Carmen Griñan-Lison; Jose L Blaya-Cánovas; Araceli López-Tejada; Marta Ávalos-Moreno; Alba Navarro-Ocón; Francisca E Cara; Adrián González-González; Jose A Lorente; Juan A Marchal; Sergio Granados-Principal Journal: Antioxidants (Basel) Date: 2021-01-31
Authors: Alba Navarro-Ocón; Jose L Blaya-Cánovas; Araceli López-Tejada; Isabel Blancas; Rosario M Sánchez-Martín; María J Garrido; Carmen Griñán-Lisón; Jesús Calahorra; Francisca E Cara; Francisco Ruiz-Cabello; Juan A Marchal; Natalia Aptsiauri; Sergio Granados-Principal Journal: Pharmaceutics Date: 2022-02-25 Impact factor: 6.321